title: [Expression and significance of C-kit and platelet-derived growth factor receptor-beta (PDGFRbeta) in esophageal carcinoma].
abstract: OBJECTIVE
  Some researches have showed that STI-571 could inhibit tyrosine kinase of Bcr-Abl, C-kit, and platelet-derived growth factor receptor-beta (PDGFRbeta), therefore, inhibit cell differentiation and proliferation and accelerate cell apoptosis. This study was to examine the expression of tyrosine kinase receptor C-kit and PDGFRbeta, which is correlated to STI-571, in esophageal carcinoma.
  
  
  METHODS
  The expression of C-kit and PDGFRbeta in tumor tissue, para-tumor tissue, and normal tissue of 50 specimens of esophageal carcinoma was examined by immunohistochemistry.
  
  
  RESULTS
  The strong expression rate of C-kit was low in tumor, para-tumor, and normal tissues (4%, 4%, and 12%, respectively), with no significant difference (P=0.220). The strong expression rate of PDGFRbeta was significantly higher in tumor tissues than in para-tumor and normal tissues (68% vs. 28% and 28%, P=0.001). Logistic regression analysis revealed that the strong expression rate of C-kit and PDGFRbeta had no correlation to sex, age, differentiation degree, infiltrative depth, position, lymph node metastasis, and stage of esophageal carcinoma.
  
  
  CONCLUSIONS
  The strong expression rate of PDGFRbeta is significantly higher in tumor tissues than in para-tumor and normal tissues. The strong expression rate of C-kit in normal esophageal tissues is low, and it is lower in para-tumor and tumor tissues.
authors.affiliation: State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Xu
authors.initials: X
authors.lastname: Zhang
authors.forename: Tie-Hua
authors.initials: TH
authors.lastname: Rong
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.forename: Hao
authors.initials: H
authors.lastname: Long
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Fu
authors.forename: Peng
authors.initials: P
authors.lastname: Ling
authors.forename: Lan-Jun
authors.initials: LJ
authors.lastname: Zhang
authors.forename: Ming-Tian
authors.initials: MT
authors.lastname: Yang
authors.forename: Can-Guang
authors.initials: CG
authors.lastname: Zeng
authors.forename: Guo-Wei
authors.initials: GW
authors.lastname: Ma
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Su
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Li
authors.forename: Jun-Ye
authors.initials: JY
authors.lastname: Wang
authors.forename: Zhe-Sheng
authors.initials: ZS
authors.lastname: Wen
authors.forename: Jin-Ming
authors.initials: JM
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D002462:Cell Membrane / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000473:pathology; D004947:Esophagus / Q000378:metabolism; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000378:metabolism*
chemical_list: D019009:Proto-Oncogene Proteins c-kit; D020797:Receptor, Platelet-Derived Growth Factor beta